219 related articles for article (PubMed ID: 23090979)
1. The anticancer ruthenium complex KP1019 induces DNA damage, leading to cell cycle delay and cell death in Saccharomyces cerevisiae.
Stevens SK; Strehle AP; Miller RL; Gammons SH; Hoffman KJ; McCarty JT; Miller ME; Stultz LK; Hanson PK
Mol Pharmacol; 2013 Jan; 83(1):225-34. PubMed ID: 23090979
[TBL] [Abstract][Full Text] [Related]
2. DNA Damage Response Checkpoint Activation Drives KP1019 Dependent Pre-Anaphase Cell Cycle Delay in S. cerevisiae.
Bierle LA; Reich KL; Taylor BE; Blatt EB; Middleton SM; Burke SD; Stultz LK; Hanson PK; Partridge JF; Miller ME
PLoS One; 2015; 10(9):e0138085. PubMed ID: 26375390
[TBL] [Abstract][Full Text] [Related]
3. Anti-cancer drug KP1019 modulates epigenetics and induces DNA damage response in Saccharomyces cerevisiae.
Singh V; Azad GK; Mandal P; Reddy MA; Tomar RS
FEBS Lett; 2014 Mar; 588(6):1044-52. PubMed ID: 24561198
[TBL] [Abstract][Full Text] [Related]
4. Proteomic analysis of the S. cerevisiae response to the anticancer ruthenium complex KP1019.
Stultz LK; Hunsucker A; Middleton S; Grovenstein E; O'Leary J; Blatt E; Miller M; Mobley J; Hanson PK
Metallomics; 2020 Jun; 12(6):876-890. PubMed ID: 32329475
[TBL] [Abstract][Full Text] [Related]
5. Anti-cancer drug KP1019 induces Hog1 phosphorylation and protein ubiquitylation in Saccharomyces cerevisiae.
Singh V; Azad GK; Reddy M A; Baranwal S; Tomar RS
Eur J Pharmacol; 2014 Aug; 736():77-85. PubMed ID: 24797784
[TBL] [Abstract][Full Text] [Related]
6. Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A).
Heffeter P; Pongratz M; Steiner E; Chiba P; Jakupec MA; Elbling L; Marian B; Körner W; Sevelda F; Micksche M; Keppler BK; Berger W
J Pharmacol Exp Ther; 2005 Jan; 312(1):281-9. PubMed ID: 15331656
[TBL] [Abstract][Full Text] [Related]
7. A postincision-deficient TFIIH causes replication fork breakage and uncovers alternative Rad51- or Pol32-mediated restart mechanisms.
Moriel-Carretero M; Aguilera A
Mol Cell; 2010 Mar; 37(5):690-701. PubMed ID: 20227372
[TBL] [Abstract][Full Text] [Related]
8. The requirement of yeast Ssl2 (Rad25) for the repair of cisplatin-damaged DNA.
Yang WL; Cvijic ME; Ishii K; Chin KV
Biochem Biophys Res Commun; 1998 Sep; 250(3):593-7. PubMed ID: 9784390
[TBL] [Abstract][Full Text] [Related]
9. A specific transcriptional response of yeast cells to camptothecin dependent on the Swi4 and Mbp1 factors.
Lotito L; Russo A; Bueno S; Chillemi G; Fogli MV; Capranico G
Eur J Pharmacol; 2009 Jan; 603(1-3):29-36. PubMed ID: 19094980
[TBL] [Abstract][Full Text] [Related]
10. EPR as a probe of the intracellular speciation of ruthenium(III) anticancer compounds.
Webb MI; Walsby CJ
Metallomics; 2013 Dec; 5(12):1624-33. PubMed ID: 24057014
[TBL] [Abstract][Full Text] [Related]
11. From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).
Hartinger CG; Zorbas-Seifried S; Jakupec MA; Kynast B; Zorbas H; Keppler BK
J Inorg Biochem; 2006 May; 100(5-6):891-904. PubMed ID: 16603249
[TBL] [Abstract][Full Text] [Related]
12. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
Malik M; Nitiss KC; Enriquez-Rios V; Nitiss JL
Mol Cancer Ther; 2006 Jun; 5(6):1405-14. PubMed ID: 16818498
[TBL] [Abstract][Full Text] [Related]
13. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
14. DNA interstrand cross-link repair in the Saccharomyces cerevisiae cell cycle: overlapping roles for PSO2 (SNM1) with MutS factors and EXO1 during S phase.
Barber LJ; Ward TA; Hartley JA; McHugh PJ
Mol Cell Biol; 2005 Mar; 25(6):2297-309. PubMed ID: 15743825
[TBL] [Abstract][Full Text] [Related]
15. Transcription factor b (TFIIH) is required during nucleotide-excision repair in yeast.
Wang Z; Svejstrup JQ; Feaver WJ; Wu X; Kornberg RD; Friedberg EC
Nature; 1994 Mar; 368(6466):74-6. PubMed ID: 8107888
[TBL] [Abstract][Full Text] [Related]
16. Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae.
Simon JA; Szankasi P; Nguyen DK; Ludlow C; Dunstan HM; Roberts CJ; Jensen EL; Hartwell LH; Friend SH
Cancer Res; 2000 Jan; 60(2):328-33. PubMed ID: 10667584
[TBL] [Abstract][Full Text] [Related]
17. Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019.
Bartel C; Egger AE; Jakupec MA; Heffeter P; Galanski MS; Berger W; Keppler BK
J Biol Inorg Chem; 2011 Dec; 16(8):1205-15. PubMed ID: 21706338
[TBL] [Abstract][Full Text] [Related]
18. DNA damage-processing pathways involved in the eukaryotic cellular response to anticancer DNA cross-linking drugs.
Beljanski V; Marzilli LG; Doetsch PW
Mol Pharmacol; 2004 Jun; 65(6):1496-506. PubMed ID: 15155842
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
[TBL] [Abstract][Full Text] [Related]
20. Saccharomyces cerevisiae as a model system to study the response to anticancer agents.
Matuo R; Sousa FG; Soares DG; Bonatto D; Saffi J; Escargueil AE; Larsen AK; Henriques JA
Cancer Chemother Pharmacol; 2012 Oct; 70(4):491-502. PubMed ID: 22851206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
